In August, a World Federation of Hemophilia (WFH) workshop was held on the topic of using novel therapies to treat patients with bleeding disorders who have developed inhibitors. The two-day event took place in Dubai, U.A.E, and saw several WFH board members give talks, including Glenn Pierce, MD, PhD, Vice President, Medical; Assad Haffar, MD, Medical & Humanitarian Aid Director; Magdy El-Ekiaby, MD, medical board member and Saliou Diop, MD, WFH Medical board member.
The workshop—which was developed as part of the WFH Humanitarian Aid Program—featured a number of talks from different international experts in the field. The agenda covered challenges in diagnosis and management; unmet needs in inhibitors management; managing breakthrough bleeds; managing patients undergoing surgery; temperature monitoring, record keeping and reporting. Attendees also had the chance to discuss priorities for the management care of people with a bleeding disorder in developing countries.
The event also saw a significant amount of time dedicated to listening to representatives from several countries share their experience in treating with extended half-life (EHL) clotting factor concentrates and conventional donated products. Speakers from Cameroon, Congo, Madagascar, Malawi, Myanmar, Nepal, Senegal, Sri Lanka, Tanzania, Uganda, Venezuela, and Zambia, all shared their knowledge in order to help attendees optimize how they manage care with their patients.
About the WFH Humanitarian Aid Program
The expanded WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Visionary Contributors; Grifols, CSL Behring, GC Pharma, our Corporate partners; and Roche and Bayer, our newest donors. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.